US patent 9,486,464 covers the composition and method of manufacture of dietary supplement compositions with a synergistic combination of saffron and resveratrol. Persavita’s Saffron 2020 is a nutritional supplement that is formulated to help maintain general eyesight and to support eye health in aged-related macular degeneration (AMD) and cataracts.
“We know Saffron 2020 is special, and we are thrilled to reach this milestone” says Mahmood Piraee, PhD, PharmD, Persavita CEO. “We've witnessed amazing outcomes among people taking Saffron 2020, and the patent allows Persavita to offer it to more people suffering from AMD or trying to maintain their general eye health.”
Saffron 2020 is formulated with “precise, optimal levels of the most important eye health ingredients, including 20mg of highest quality saffron”, said the company. It also contains resveratrol, lutein and zeaxanthin.